Monitoring Artemether-Lumefantrin (ALU) and Artesunate-Amodiaquin (AS-AQ) efficacy in uncomplicated malaria treatment in Bandiagara, and Doneguebougou

Not Applicable

• Conditions: Malaria

• Registration Number: PACTR201409000702188
• Lead Sponsor: WANETAM/MRTC/DEAP/FMOS/USTTB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-09
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

age between 6 months-70 years;
-résident in Bandiagara and area of Donéguébougou during study follow up periode ;
-Be able to take tablet per os
-Body temperature ¿ 37,5 degree Celsius or history of fievre within last 24 hours;
-Plasmodium falciparum infection parasitemia between 2000 et 200 000 asexual forms/ul associated or not with P. ovale, P. malaria and/or P. vivax ;
-consent of participant or/and parent (ou guardian) for children

Exclusion Criteria

Clinical signs of severe malaria or cerebral malaria according to WHO criteria
- Patients with severe concomitant disease
- Concomitant febrile disorders (otitis, Acute chest infection, tonsillitis and others)
- Have a lower than 8 g / dl hemoglobin;
- Known to be allergic to artemisinin derivatives;
- Have a documented decision CTA in the last fifteen (15) days.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to parasite clearance, Proportion of subjects with Clinical and Parasitological Response Adequate, Proportion of subjects with parasitaemia on day 3

Secondary Outcome Measures

Name	Time	Method
Time to gametocytes clearance;Time to fever clearance